GlassScriptPhysician profile
Kara Coleman
NPI 1558740415
$1,447.63
in general payments reported to CMS, 2019-2025
24 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.27 · 2021: $144 · 2022: $210 · 2023: $237 · 2024: $447 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.33 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $191.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.34 | 2024-2025 | Jardiance |
| Daiichi Sankyo INC. | $99.32 | 2023-2024 | Injectafer |
| Lilly USA, LLC | $89.54 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $88.02 | 2021-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $79.16 | 2023-2025 | Verquvo, Vaxneuvance, Capvaxive |
| Glaxosmithkline, LLC. | $62.90 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $52.78 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $39.64 | 2021-2023 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $28.98 | 2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $28.79 | 2024 | |
| Esperion Therapeutics, INC. | $28.55 | 2023-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $21.84 | 2022 | |
| Biogen, INC. | $21.35 | 2024 | Spinraza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $20.41 | 2022 | |
| Hologic Sales and Service, LLC | $19.06 | 2025 | Thinprep 2000 Processor, Aptima |
| Genentech USA, INC. | $18.27 | 2020 | |
| Astellas Pharma US INC | $18.25 | 2024 | Veozah |
| Jazz Pharmaceuticals INC. | $17.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.15 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $14.87 | 2025 | Breztri |
| Cranial Technologies, INC | $14.85 | 2025 | Doc Band |
| Phathom Pharmaceuticals, INC. | $13.94 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.